Compare Dishman Pharma with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs GLENMARK PHARMA - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA GLENMARK PHARMA DISHMAN PHARMA/
GLENMARK PHARMA
 
P/E (TTM) x 25.1 17.2 146.2% View Chart
P/BV x 3.3 2.8 118.7% View Chart
Dividend Yield % 0.7 0.4 186.0%  

Financials

 DISHMAN PHARMA   GLENMARK PHARMA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
GLENMARK PHARMA
Mar-19
DISHMAN PHARMA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs374712 52.6%   
Low Rs129484 26.7%   
Sales per share (Unadj.) Rs197.8349.6 56.6%  
Earnings per share (Unadj.) Rs21.232.8 64.7%  
Cash flow per share (Unadj.) Rs34.744.3 78.3%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.80.3 237.5%  
Book value per share (Unadj.) Rs179.9198.6 90.6%  
Shares outstanding (eoy) m80.69282.17 28.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.31.7 74.4%   
Avg P/E ratio x11.918.2 65.1%  
P/CF ratio (eoy) x7.213.5 53.8%  
Price / Book Value ratio x1.43.0 46.5%  
Dividend payout %9.46.1 154.6%   
Avg Mkt Cap Rs m20,306168,625 12.0%   
No. of employees `0000.812.0 6.9%   
Total wages/salary Rs m5,35520,561 26.0%   
Avg. sales/employee Rs Th19,252.78,196.0 234.9%   
Avg. wages/employee Rs Th6,459.51,708.1 378.2%   
Avg. net profit/employee Rs Th2,064.1768.5 268.6%   
INCOME DATA
Net Sales Rs m15,96198,655 16.2%  
Other income Rs m2652,081 12.8%   
Total revenues Rs m16,226100,736 16.1%   
Gross profit Rs m4,10315,858 25.9%  
Depreciation Rs m1,0913,259 33.5%   
Interest Rs m9443,346 28.2%   
Profit before tax Rs m2,33411,335 20.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m01,672 0.0%   
Tax Rs m6243,756 16.6%   
Profit after tax Rs m1,7119,250 18.5%  
Gross profit margin %25.716.1 159.9%  
Effective tax rate %26.733.1 80.6%   
Net profit margin %10.79.4 114.3%  
BALANCE SHEET DATA
Current assets Rs m11,01866,968 16.5%   
Current liabilities Rs m9,51740,211 23.7%   
Net working cap to sales %9.427.1 34.7%  
Current ratio x1.21.7 69.5%  
Inventory Days Days11083 132.6%  
Debtors Days Days3581 42.9%  
Net fixed assets Rs m16,30433,322 48.9%   
Share capital Rs m161282 57.2%   
"Free" reserves Rs m12,90755,770 23.1%   
Net worth Rs m14,51656,052 25.9%   
Long term debt Rs m4,18935,738 11.7%   
Total assets Rs m29,805132,888 22.4%  
Interest coverage x3.54.4 79.1%   
Debt to equity ratio x0.30.6 45.3%  
Sales to assets ratio x0.50.7 72.1%   
Return on assets %8.99.5 94.0%  
Return on equity %11.816.5 71.4%  
Return on capital %17.517.8 98.4%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,95262,998 7.9%   
Fx outflow Rs m69722,859 3.0%   
Net fx Rs m4,25540,140 10.6%   
CASH FLOW
From Operations Rs m2,78613,242 21.0%  
From Investments Rs m-1,529-6,990 21.9%  
From Financial Activity Rs m-941-7,387 12.7%  
Net Cashflow Rs m316-2,971 -10.7%  

Share Holding

Indian Promoters % 61.4 48.3 127.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 6.9 53.6%  
FIIs % 12.7 34.4 36.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 10.5 210.5%  
Shareholders   46,261 56,727 81.6%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   BIOCON   CADILA HEALTHCARE  ORCHID PHARMA  DIVIS LABORATORIES  UNICHEM LAB  

Compare DISHMAN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Lower, Dow Futures Up by 18 Points(12:30 pm)

Share markets in India are presently trading marginally lower. The BSE Sensex is trading down by 17 points, flat at 48,064 levels.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 132.5% (Quarterly Result Update)

Sep 1, 2020 | Updated on Sep 1, 2020

For the quarter ended June 2020, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 132.5% YoY). Sales on the other hand came in at Rs 23 bn (up 0.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

Top 3 Nifty ETFs to Buy Now(Fast Profits Daily)

Apr 20, 2021

In this video I tell you the three Nifty ETFs I think are the best.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

11x Bankruptcy to Bluechip Stock: A Rare India Revival Story(Profit Hunter)

Apr 16, 2021

There is no stopping this 11-bagger stock from significant upside.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS